Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular risk reduction and should be considered first-line therapy for patients with type 2 diabetes and established cardiovascular disease.
If you have Type 2 Diabetes and existing heart disease, ask your doctor about SGLT2 inhibitors (like empagliflozin) or GLP-1 receptor agonists (like semaglutide). These drugs are now considered first-line because they protect your heart and reduce the risk of heart attack and stroke, in addition to controlling blood sugar. This is more important than just lowering your A1C number.
Some glucose-lowering drug classes, namely SGLT2-inhibitors and GLP-1 receptor agonists, offer significant benefits on the level of cardiovascular risk reduction and are thus a powerful addition to the clinical management armamentarium in CVD and diabetes.
Why this rating
Based on multiple dedicated CV outcome trials and meta-analyses cited in the paper.
Source
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
Waleed AlHabeeb et al. · Journal of the Saudi Heart Association · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →